Adamis Pharmaceuticals Corp
Formerly Cellegy Pharmaceuticals Inc.
Adamis Pharmaceuticals Corp is listed today as Adamis Pharmaceuticals Corporation: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2020 | $6 M | No. 3 | $2 to $10 million | options | SEC | |
| Jun 2013 | $7 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Jun 2011 | $3 M | No. 1 | $2 to $10 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Adamis Pharmaceuticals Corp chose not to state its revenue in its newest notice of a funding round (Mar 2020).
SEC Form D · Mar 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2020
That is all the official record says: Adamis Pharmaceuticals Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Adamis Pharmaceuticals Corp are on record.
Investors#
No investor of Adamis Pharmaceuticals Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 11 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David J Marguglio | Executive officer | Mar 2020 |
| Dennis J Carlo | Executive officer | Mar 2020 |
| Karen K Daniels | Executive officer | Mar 2020 |
| Robert O Hopkins | Maxim Group LLC received sales commissions of $403,680 in connection with a concurrent registered direct offering by the | Mar 2020 |
| Ronald B Moss | Executive officer | Mar 2020 |
| Craig A Johnson | Executive officer | Jul 2013 |
| Thomas K Moll | Executive officer | Jul 2013 |
| David J. Marguglio | Executive officer | Apr 2012 |
| Dennis J. Carlo | Executive officer | Apr 2012 |
| Karen K. Daniels | Executive officer | Apr 2012 |
| David J Marguglio | Director | Mar 2020 |
| Dennis J Carlo | Director | Mar 2020 |
| Howard C Birndorf | Director | Mar 2020 |
| Richard C Williams | Director | Mar 2020 |
| Roshawn C Blunt | Director | Mar 2020 |
| Karen K Daniels | Director | Jul 2013 |
| Kenneth M Cohen | Director | Jul 2013 |
| Robert O Hopkins | Director | Jul 2013 |
| Tina S Nova, Ph. D. | Director | Jul 2013 |
| Craig S. Johnson | Director | Apr 2012 |
| David J. Marguglio | Director | Apr 2012 |
| Dennis J. Carlo | Director | Apr 2012 |
| Kenneth M. Cohen | Director | Apr 2012 |
| Tina S. Nova, Ph.D | Director | Apr 2012 |
About
Pharmaceutical company in San Diego, United States.